We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
(+12%)
Cap. Flow
+$3.01B
Cap. Flow
% of AUM
28.27%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$96.9M |
| 2 |
Merck
MRK
|
+$73.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$57.1M |
| 4 |
Illumina
ILMN
|
+$40.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$57.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$51.7M |
| 3 |
Kimberly-Clark
KMB
|
+$28.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.5M |
| 5 |
Arista Networks
ANET
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.77% |
| 2 | Technology | 20.35% |
| 3 | Consumer Discretionary | 9.49% |
| 4 | Communication Services | 7.69% |
| 5 | Financials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Supernus Pharmaceuticals
SUPN
$2.7B
| $417K | ﹤0.01% |
20,000
-14,000
| -41% | -$318K |
|
702
CGI
GIB
$15.4B
| $402K | ﹤0.01% |
5,939
| – | – |
|
703
Live Nation Entertainment
LYV
$42.9B
| $402K | ﹤0.01% |
+7,465
| New | +$385K |
|
704
Zscaler
ZS
$24.9B
| $401K | ﹤0.01% |
2,850
| – | – |
|
705
Voya Financial
VOYA
$8.96B
| $396K | ﹤0.01% |
8,265
+2,947
| +55% | +$145K |
|
706
Gold Fields
GFI
$28.8B
| $359K | ﹤0.01% |
29,200
+3,767
| +15% | +$46.3K |
|
707
Fortune Brands Innovations
FBIN
$5.86B
| $346K | ﹤0.01% |
4,680
-984
| -17% | -$65.8K |
|
708
Devon Energy
DVN
$51.3B
| $343K | ﹤0.01% |
36,238
-107,259
| -75% | -$1.13M |
|
709
Teradyne
TER
$50B
| $343K | ﹤0.01% |
4,313
| – | – |
|
710
Albemarle
ALB
$13.4B
| $320K | ﹤0.01% |
3,585
-1,665
| -32% | -$148K |
|
|
AYX
711
DELISTED
Alteryx Inc
AYX
| $320K | ﹤0.01% |
2,820
| – | – |
|
712
KB Financial Group
KB
$39.5B
| $315K | ﹤0.01% |
9,792
+2,279
| +30% | +$70.6K |
|
713
Cemex
CX
$16.9B
| $308K | ﹤0.01% |
81,075
| – | – |
|
714
Huntington Ingalls Industries
HII
$11B
| $303K | ﹤0.01% |
2,155
-30,105
| -93% | -$4.84M |
|
715
iShares US Pharmaceuticals ETF
IHE
$1.49B
| $294K | ﹤0.01% |
5,400
| – | – |
|
|
FLIR
716
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $293K | ﹤0.01% |
8,171
-2,214
| -21% | -$84.4K |
|
|
GAP
717
The Gap Inc
GAP
$7.3B
| $283K | ﹤0.01% |
16,601
+612
| +4% | +$9.12K |
|
718
Fox Class A
FOXA
$24.8B
| $273K | ﹤0.01% |
9,798
+373
| +4% | +$9.87K |
|
719
Federal Realty Investment Trust
FRT
$10.9B
| $268K | ﹤0.01% |
3,647
-245
| -6% | -$19.3K |
|
720
ARK Genomic Revolution ETF
ARKG
$1.53B
| $255K | ﹤0.01% |
+4,000
| New | +$234K |
|
|
ZEN
721
DELISTED
ZENDESK INC
ZEN
| $254K | ﹤0.01% |
2,470
| – | – |
|
722
United Microelectronic
UMC
$42.9B
| $252K | ﹤0.01% |
52,694
+17,193
| +48% | +$63.8K |
|
723
State Street SPDR S&P Biotech ETF
XBI
$10B
| $252K | ﹤0.01% |
2,265
| – | – |
|
724
Mohawk Industries
MHK
$6.91B
| $247K | ﹤0.01% |
2,536
-503
| -17% | -$45.2K |
|
725
Lear
LEA
$7.39B
| $240K | ﹤0.01% |
2,205
+182
| +9% | +$20.7K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2020 Portfolio in Review
As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.
- Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
- Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
- Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
- Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
- Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
- Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
- Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.